Literature DB >> 6447563

Multiple concurrent immunoregulatory defects in cancer patients with depressed PHA-induced lymphocyte DNA synthesis.

D P Braun, M A Cobleigh, J E Harris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 6447563     DOI： 10.1016/0090-1229(80)90076-8

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN： 0090-1229


× No keyword cloud information.
  7 in total

1.  Modulation of in vitro antitumor immunity in response to the biological activators interleukin-2, gamma interferon, and granulocyte monocyte-colony stimulating factor in the peripheral blood of cancer patients receiving cytotoxic chemotherapy.

Authors:  J E Harris; D P Braun
Journal:  Bull N Y Acad Med       Date:  1989-01

2.  Inhibition of mitogen-activated proliferation of human lymphocytes by hypochlorous acid in vitro: protection and reversal by ascorbate and cysteine.

Authors:  M J Smit; R Anderson
Journal:  Agents Actions       Date:  1990-06

3.  Serial immune testing in surgically resected lung cancer patients.

Authors:  D P Braun; S Nisius; A Hollinshead; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1983       Impact factor: 6.968

4.  Surface phenotypes of human peripheral blood mononuclear cells from patients with gastrointestinal carcinoma.

Authors:  G Boltz; E Penner; C Holzinger; S Bakos; A Fellinger; M Walgram; C Wiltschke; H Rumpold; K Langer; A Gangl
Journal:  J Cancer Res Clin Oncol       Date:  1987       Impact factor: 4.553

5.  Chemiluminescence, suppression and cytotoxicity in peripheral blood mononuclear cells from solid tumor cancer patients.

Authors:  D P Braun; K P De Boer; J E Harris
Journal:  Cancer Immunol Immunother       Date:  1982       Impact factor: 6.968

6.  Plasma glutamate concentration and lymphocyte activity.

Authors:  W Dröge; H P Eck; M Betzler; P Schlag; P Drings; W Ebert
Journal:  J Cancer Res Clin Oncol       Date:  1988       Impact factor: 4.553

7.  Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer.

Authors:  K J McCormick; W R Panje
Journal:  Cancer Immunol Immunother       Date:  1986       Impact factor: 6.968
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.